41 results about "Oxidized ldl" patented technology

The present invention relates to an antigenic composition capable of eliciting antibodies by interacting with alphabeta chains of a T cell receptor (TcR), which composition is comprised of a peptide-aldehyde conjugate. The aldehyde portion may be a dialdehyde, such as malondialdehyde (MDA), or a monoaldehyde, such as 4-hydroxynonenal (4-HNE), while the peptide portion preferably comprises at least one lysine residue. The antigenic composition according to the invention is capable of recognizing and interacting with a TcR having a complementarity-determining region 3 (CDR3) of alpha10 and beta6 chains that comprises a cluster of charged and polar amino acids. The invention also relates to a method of producing a vaccine against atherosclerosis by screening of a library of candidate compounds for their ability to bind to a conjugate of oxidized LDL and a dialdehyde as well as to such a vaccine as such.

The present invention discloses oxygenic oxygenic oxysterols. Also disclosed, agents and methods for protecting, blocking or rescuing marrow stromal cells from the inhibitory effects of oxidative stress on their osteoblastic cellular differentiation. Exemplary agents include oxysterols, rhBMP2, alone or in combination which are demonstrated to specifically combat oxidative stress caused by inflammatory oxidized lipids, such as xanthine / xanthine oxidase and minimally oxidized LDL. The synergistic effects of oxysterols and bone morphogenic proteins are disclosed.

There is provided a method of inhibiting the occurrence of one of more of the following conditions:—the proliferation of monocytes / macrophages; or—the proliferation of smooth muscle cells; or—the expression of CD36 receptors; or—the uptake of oxidized LDL, the method comprising the step of administering an effective amount of one or more phosphate derivatives of one or more electron transfer agents.

The invention proposes the sure of reduced glutathione in a liposome (liposomal reduced glutathione) for the oral administration of a therapeutically effective amount to ameliorate the progression of vascular disease, including atherosclerosis, diabetes, hypertension, narrowing of arteries leading to decreased blood flow, ischemic events, and the formation of blood clots, abnormal platelet aggregation, and thrombotic events, by reducing the amount and effect of oxidized cholesterol, oxidized HDL and oxidized LDL. The invention also proposes combining liposomal encapsulated glutathione with statin drugs to improve the effect of lowering not only cholesterol but also the oxidized cholesterol as well as oxidized HDL and oxidized LDL. The invention also proposes combining liposomal encapsulated glutathione with CoQ10 as a therapy for vascular disease and management of side effects of statin therapy.

A method for diagnosing the likelihood and severity of cardiovascular disease in a patient is disclosed. The method determines the levels of antibodies against autoantigens, including myosin, oxidized LDL, β-2-glycoprotein, heat shock protein-60, platelet glycoprotein, and immune complexes. It then compares the results to normal levels to determine the likelihood and severity of cardiovascular disease.

The present invention includes compositions and methods for targeting the LOX-1 receptor on immune cells and uses for the anti-LOX-1 antibodies.

The present invention relates to the use of Heat Shock Proteins and fragments thereof as targeting ligand. The Heat Shock Protein may be labeled with imaging agents that are capable of binding lectin-like oxidized low-density lipoprotein (LOX-1) or may be attached to a therapeutic agent. The sequences are useful for the diagnosis and monitoring of diseases as well as means for internalizing signaling moieties and therapeutics.

There is provided a method of therapy of atherosclerosis, by providing microRNA let-7g, an analogue thereof or modified let-7g to organisms to inhibit the expression of lectin-like oxidized low density lipoprotein receptor-1 (LOX-1), and the binding of LOX-1 and oxidized low-density lipoprotein (oxLDL), so as to block the pathogenesis of atherosclerosis. Also, a method of diagnosis of atherosclerosis comprises determining the levels of microRNA let-7g in serum or plasma samples of organisms, in which the levels of microRNA let-7g is estimated in individuals with atherosclerosis as compared to individuals without atherosclerosis.

From antibodies that can be used to immunostain atherosclerotic tissue sections, the present inventors selected antibodies applicable to in vivo imaging, and analyzed their specificities. The result showed that fluorescently labeled anti-oxidized LDL / β2GPI complex antibodies that are specific to a particular epitope were effective for imaging.

Provided is a monoclonal antibody against slightly oxidized LDL, which can play a role as an important tool in the research and development of oxidized LDL. Also provided are a kit for the simple detection of slightly oxidized LDL and a method for the simple detection of slightly oxidized LDL from the biological sample of a subject to be tested which use the monoclonal antibody. By means of ELISA (Enzyme-Linked Immunosorbent Assay) using the monoclonal antibody as the solid phase antibody and an anti-apolipoprotein B antibody as the detection antibody, the degree of reaction between a severely oxidized low-density lipoprotein and the monoclonal antibody is low in comparison to the degree of reaction between a slightly oxidized low-density lipoprotein and the monoclonal antibody, and the monoclonal antibody specifically reacts with an oxidized low-density lipoprotein.

Immunoreactive compositions and methods for immunizing animal, including, humans, cows, and fowl, against cholesterol and cholesterol derivatives, including cholesterol oxides, and their use in methods for reducing and preventing lipid raft-based diseases, including, but not limited to HIV-1, SARS, prion formation in Creutzfeldt-Jakob disease, and neutralizing oxidized modified lipoproteins, specifically, oxidized-LDL, oxidized-VLDL / IDL, and oxidized-chylomicrons, which contribute to the formation of fatty streaks and atherosclerotic plaques, are described.

Cardiac disease is the world's leading cause of death. Cardiac Disease's pathogenesis is largely attributed to cholesterol, predominantly carried by low-density lipoproteins (LDL). However, recent research has found that oxidized-LDL is significantly more potent in the initiation and development of atherosclerosis. Tests for both cholesterol and ox-LDL tests are lab-based and expensive. With every third American at risk for Cardiac Disease, this invention discloses an on-site, ultra-low cost, rapid diagnostic test. The diagnostic test disclosed will enable a holistic assessment of Cardiac Disease risk. Furthermore, portability and ultra low-cost of the test put vital health data in the hands of patients and doctors. Additionally, the inkjet printing system disclosed can be used to mass produce the test strips on demand.

A purified polypeptide having an amino acid sequence that is substantial identical with the amino acid sequence of SEQ ID NO:1, SEQ ID NO:3, or both, in which the polypeptide binds low density lipoproteins (LDL) or oxidized LDL (oxLDL), or both, and particularly binds well to LDL cholesterol and oxidized LDL cholesterol. The polypeptide may be used in combination with conventional adjuvants or carrier substances for producing a drug having a fat-reducing effect and for producing drugs for aiding in the treatment of renal diseases.

The invention provides antiarterioscierosis agents containing as the active ingredient porphyrin derivatives or ester derivatives thereof as represented by the general formula (1) or (2); and foods or pharmaceutical compositions containing the agents. The porphyrin derivatives and the ester derivatives thereof exhibit an effect of inhibiting the bonding of oxidized LDL to LOX-1 expressed in vascular endothelial cells, macrophage an so on and an antagonistic effect of inhibiting the incorporation of oxidized LDL into cells through LOX-1, and are highly safe. [Chemical formula 1] (wherein R1 and R2 are each a hydrocarbon group having 1 to 4 carbon atoms or the like; and R3 to R8 are each a hydrocarbon group having 1 to 2 carbon atoms, formyl, or the like) [Chemical formula 2] (wherein R1 and R2 are each a hydrocarbon group having 1 to 4 carbon atoms or the like; and R3 to R8 are each a hydrocarbon group having 1 to 2 carbon atoms, formyl, or the like)